- Home
- PCRX vs ROOT Comparison
PCRX vs ROOT Comparison
Compare PCRX & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCRX | ROOT |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | 829 | 1256 |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.1M | 881.4M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCRX | ROOT |
|---|---|---|
| Price | $24.88 | $54.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $30.25 | ★ $92.40 |
| AVG Volume (30 Days) | ★ 417.8K | 250.7K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | 28.96 |
| EPS | 0.07 | ★ 2.09 |
| Revenue | $541,533,000.00 | ★ $1,517,100,000.00 |
| Revenue This Year | $6.78 | $11.73 |
| Revenue Next Year | $8.54 | $12.80 |
| P/E Ratio | $360.57 | ★ $26.65 |
| Revenue Growth | 26.04 | ★ 28.95 |
| 52 Week Low | $18.80 | $40.91 |
| 52 Week High | $27.64 | $134.00 |
Technical Indicators
Market Signals| Indicator | PCRX | ROOT |
|---|---|---|
| Relative Strength Index (RSI) | 66.50 | 52.26 |
| Support Level | $21.87 | $50.09 |
| Resistance Level | $25.06 | $58.97 |
| Average True Range (ATR) | 0.79 | 3.32 |
| MACD | 0.24 | -0.04 |
| Stochastic Oscillator | 83.15 | 65.93 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.